ADVFN Logo ADVFN
市場データ
ニュース
投資ツール
市場
発見

Hot Features

Follow Feed

フォローフィードコミュニティでトレーダーや投資家とつながりましょう.

ライブオプションフロー

包括的なオプション データを調査し、オプション フローで高度なフィルターを使用します.

モニター

ターミナル モニターで株式と資産のウォッチリストを整理および監視します
サインイン Premium Iconプレミアム Help Menu
Bitcoin
64,738.54
-2.63%
S&P 500
5,484.42
0.20%
Dow Jones
38,857.63
0.21%
US Dollar vs Yen
157.8515
0.09%
Brent Oil
83.795
-0.13%
Registration Strip Icon for discussion 登録して、同じ考えを持つ投資家と議論するためのアクティブなフォーラムで相互作用するためのアクティブなフォーラムに参加してください。
登録
  1. ホーム
  2. 投資
  3. 株式
  4. アメリカ
  5. NASDAQ
  6. Theravance Biopharma Inc (TBPH)

  7. Theravance Biopharma Inc (TBPH) ニュース

TBPH

Theravance Biopharma (TBPH)

Theravance Biopharma Inc
から:
次の項目別のソート:
 Showing the most relevant articles for your search:NASDAQ:TBPH
日付受信時刻ニュースソース見出しコード企業名
2024/06/1205 : 17Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:TBPHTheravance Biopharma Inc
2024/05/2307 : 08Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:TBPHTheravance Biopharma Inc
2024/05/2307 : 06Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:TBPHTheravance Biopharma Inc
2024/05/2307 : 04Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:TBPHTheravance Biopharma Inc
2024/05/2307 : 02Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:TBPHTheravance Biopharma Inc
2024/05/1519 : 26Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:TBPHTheravance Biopharma Inc
2024/05/1405 : 13Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:TBPHTheravance Biopharma Inc
2024/05/1405 : 05PR Newswire (US)Theravance Biopharma, Inc. Reports First Quarter 2024 Financial Results and Provides Business UpdateNASDAQ:TBPHTheravance Biopharma Inc
2024/05/1107 : 10Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:TBPHTheravance Biopharma Inc
2024/05/1107 : 06Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:TBPHTheravance Biopharma Inc
2024/05/1107 : 04Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:TBPHTheravance Biopharma Inc
2024/05/1107 : 01Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:TBPHTheravance Biopharma Inc
2024/05/1005 : 15Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:TBPHTheravance Biopharma Inc
2024/05/0919 : 00PR Newswire (US)Theravance Biopharma to Participate in an Upcoming Investor ConferenceNASDAQ:TBPHTheravance Biopharma Inc
2024/04/2919 : 00PR Newswire (US)Theravance Biopharma to Report First Quarter 2024 Financial Results on May 13, 2024NASDAQ:TBPHTheravance Biopharma Inc
2024/04/1019 : 00PR Newswire (US)Theravance Biopharma, Inc. to Host Virtual Key Opinion Leader (KOL) Event to Discuss Ampreloxetine's Potential for the Treatment of Symptomatic Neurogenic Orthostatic Hypotension (nOH) in Patients with Multiple System Atrophy (MSA) on May 23, 2024NASDAQ:TBPHTheravance Biopharma Inc
2024/02/2706 : 16Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:TBPHTheravance Biopharma Inc
2024/02/2706 : 05PR Newswire (US)Theravance Biopharma, Inc. Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business UpdateNASDAQ:TBPHTheravance Biopharma Inc
2024/02/2310 : 11Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:TBPHTheravance Biopharma Inc
2024/02/2310 : 10Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:TBPHTheravance Biopharma Inc
2024/02/2310 : 08Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:TBPHTheravance Biopharma Inc
2024/02/2310 : 06Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:TBPHTheravance Biopharma Inc
2024/02/2310 : 04Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:TBPHTheravance Biopharma Inc
2024/02/2220 : 00PR Newswire (US)Theravance Biopharma to Participate in an Upcoming Investor ConferenceNASDAQ:TBPHTheravance Biopharma Inc
2024/02/1710 : 12Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:TBPHTheravance Biopharma Inc
2024/02/1506 : 00Edgar (US Regulatory)Form SC 13G - Statement of acquisition of beneficial ownership by individualsNASDAQ:TBPHTheravance Biopharma Inc
2024/02/1420 : 00PR Newswire (US)Theravance Biopharma to Report Fourth Quarter and Full Year 2023 Financial Results on February 26, 2024NASDAQ:TBPHTheravance Biopharma Inc
2024/01/1620 : 16Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:TBPHTheravance Biopharma Inc
2024/01/0520 : 07Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:TBPHTheravance Biopharma Inc
2024/01/0520 : 00PR Newswire (US)Theravance Biopharma Announces Results from the Phase 4 YUPELRI® PIFR-2 Study in Patients with Severe to Very Severe Chronic Obstructive Pulmonary Disease (COPD)NASDAQ:TBPHTheravance Biopharma Inc
 Showing the most relevant articles for your search:NASDAQ:TBPH

最近閲覧した銘柄

CCOM
US500
US 500
FX
USDGBP
US Dollar vs Sterling
SPI
SP500
S&P 500
USI
USTECH100
US Tech 100
NYSE
DIS
Walt Disney
NYSE
MCD
McDonalds
NYSE
KO
Coca Cola
NYSE
NKE
Nike
CCOM
US30
US 30
NYSE
BAC
Bank of America
NASDAQ
QQQ
Invesco QQQ Trust Series 1
AMEX
SPY
SPDR S&P 500
NASDAQ
MSFT
Microsoft
NASDAQ
AMZN
Amazon.com
NYSE
CVX
Chevron
AMEX
XLF
Financial Select Sector
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

日本
会社情報
ビジネス
人気
アプリを入手
App Store
Google Play

顧客サポート: +44 (0) 203 8794 460 | support@advfn.com

ADVFNのサービスをご利用いただくには、利用規約

© 2024 ADVFN PLC - 全著作権所有